Parkinson DiseaseNCT00539214
Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease
An observational study of Parkinson Disease, run by Boehringer Ingelheim at 317 sites in Germany.
Trial summary
To compare the effect of pramipexole on depressive symptoms in early and advanced PD patients To evaluate the course of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADS-D under pramipexole treatment To investigate whether improvement of depressive symptoms is linked to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease
- How many people
- 1,192 participants
- Where
- 317 sitesGermany
- Study dates
- Mar 2007to Dec 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: PD patients
Who may be able to join
- Idiopathic Parkinsons disease with or without fluctuations
- Indication for treatment with Sifrol®
- Male or female patients of age
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (HADS)
Who cannot join
- Any contraindications according to the Summary of Product Characteristics (SPC): hypersensitivity to pramipexole or to any of the excipients.
- Ongoing treatment with Sifrol®.
Trial locations and contacts
317 sites in 1 country.
300 sites in 1 country
Germany300 sites
Boehringer Ingelheim
Aalen
Boehringer Ingelheim
Aarbergen
Boehringer Ingelheim
Adendorf
Boehringer Ingelheim
Aham
Boehringer Ingelheim
Ahaus
Boehringer Ingelheim
Ahlen
Boehringer Ingelheim
Ahorntal
Boehringer Ingelheim
Aichach
Boehringer Ingelheim
Aislingen
Boehringer Ingelheim
Albstadt
Boehringer Ingelheim
Aldenhoven
Boehringer Ingelheim
Aldingen
Boehringer Ingelheim
Alfeld
Boehringer Ingelheim
Alpirsbach
Boehringer Ingelheim
Alsdorf
Boehringer Ingelheim
Altena
Boehringer Ingelheim
Altenstadt
Boehringer Ingelheim
Altomünster
Boehringer Ingelheim
Alveslohe
Boehringer Ingelheim
Amberg
Boehringer Ingelheim
Ammerbuch
Boehringer Ingelheim
Andernach
Boehringer Ingelheim
Anklam
Boehringer Ingelheim
Apolda
Boehringer Ingelheim
Armsheim
Boehringer Ingelheim
Arzberg
Boehringer Ingelheim
Aschaffenburg
Boehringer Ingelheim
Aschersleben
Boehringer Ingelheim
Aschheim
Boehringer Ingelheim
Attendorn
Boehringer Ingelheim
Auerbach
Boehringer Ingelheim
Augsburg
Boehringer Ingelheim
Aurich
Boehringer Ingelheim
Babensham
Boehringer Ingelheim
Backnang
Boehringer Ingelheim
Bad Arolsen
Boehringer Ingelheim
Bad Berleburg
Boehringer Ingelheim
Bad Bevensen
Boehringer Ingelheim
Bad Düben
Boehringer Ingelheim
Bad Dürrenberg
Boehringer Ingelheim
Bad Dürrheim
Boehringer Ingelheim
Bad Ems
Boehringer Ingelheim
Bad Essen
Boehringer Ingelheim
Bad Kreuznach
Boehringer Ingelheim
Bad Laasphe
Boehringer Ingelheim
Bad Langensalza
Boehringer Ingelheim
Bad Lausick
Boehringer Ingelheim
Bad Münstereifel
Boehringer Ingelheim
Bad Oeynhausen
Boehringer Ingelheim
Bad Salzungen
Boehringer Ingelheim
Bad Schwalbach
Boehringer Ingelheim
Bad Schwartau
Boehringer Ingelheim
Bad Segeberg
Boehringer Ingelheim
Bad Tennstedt
Boehringer Ingelheim
Bad Waldsee
Boehringer Ingelheim
Baden-Baden
Boehringer Ingelheim
Bahrdorf
Boehringer Ingelheim
Baltmannsweiler
Boehringer Ingelheim
Bamberg
Boehringer Ingelheim
Barleben
Boehringer Ingelheim
Bärnau
Boehringer Ingelheim
Baunatal
Boehringer Ingelheim
Bautzen
Boehringer Ingelheim
Bayreuth
Boehringer Ingelheim
Beckum
Boehringer Ingelheim
Beeskow
Boehringer Ingelheim
Bellheim
Boehringer Ingelheim
Belm
Boehringer Ingelheim
Bensheim
Boehringer Ingelheim
Berching
Boehringer Ingelheim
Bergfelde
Boehringer Ingelheim
Bergheim
Boehringer Ingelheim
Bergisch Gladbach
Boehringer Ingelheim
Berkheim
Boehringer Ingelheim
Berlin
Boehringer Ingelheim
Berne
Boehringer Ingelheim
Bernsdorf
Boehringer Ingelheim
Betzdorf
Boehringer Ingelheim
Biebertal
Boehringer Ingelheim
Bielefeld
Boehringer Ingelheim
Bienenbüttel
Boehringer Ingelheim
Bippen
Boehringer Ingelheim
Birkenfeld
Boehringer Ingelheim
Birkenwerder
Boehringer Ingelheim
Blankenhain
Boehringer Ingelheim
Blaustein
Boehringer Ingelheim
Blieskastel
Boehringer Ingelheim
Bobritzsch
Boehringer Ingelheim
Bocholt
Boehringer Ingelheim
Bochum
Boehringer Ingelheim
Bockenem
Boehringer Ingelheim
Bodelshausen
Boehringer Ingelheim
Bodenfelde
Boehringer Ingelheim
Bodenkirchen
Boehringer Ingelheim
Bodenwöhr
Boehringer Ingelheim
Bodman-Ludwigshafen
Boehringer Ingelheim
Böhlen
Boehringer Ingelheim
Bollendorf
Boehringer Ingelheim
Bonn
Boehringer Ingelheim
Bopfingen
Boehringer Ingelheim
Borgholzhausen
Boehringer Ingelheim
Borken
Boehringer Ingelheim
Borna
Boehringer Ingelheim
Bornheim
Boehringer Ingelheim
Bösel
Boehringer Ingelheim
Bottendorf
Boehringer Ingelheim
Bottmersdorf
Boehringer Ingelheim
Bottrop
Boehringer Ingelheim
Bovenden
Boehringer Ingelheim
Brake
Boehringer Ingelheim
Brandenburg
Boehringer Ingelheim
Brannenburg
Boehringer Ingelheim
Braunschweig
Boehringer Ingelheim
Brechen
Boehringer Ingelheim
Breitenbrunn
Boehringer Ingelheim
Bremen
Boehringer Ingelheim
Bremerhaven
Boehringer Ingelheim
Brensbach
Boehringer Ingelheim
Breuberg
Boehringer Ingelheim
Bruchköbel
Boehringer Ingelheim
Brunsbüttel
Boehringer Ingelheim
Buchbach
Boehringer Ingelheim
Bückeburg
Boehringer Ingelheim
Buckow
Boehringer Ingelheim
Buedelsdorf
Boehringer Ingelheim
Bünde
Boehringer Ingelheim
Burg
Boehringer Ingelheim
Burgau
Boehringer Ingelheim
Burgdorf, Hanover
Boehringer Ingelheim
Burgpreppach
Boehringer Ingelheim
Burtenbach
Boehringer Ingelheim
Büttelborn
Boehringer Ingelheim
Buttstädt
Boehringer Ingelheim
Butzbach
Boehringer Ingelheim
Cadolzburg
Boehringer Ingelheim
Calbe
Boehringer Ingelheim
Calberlah
Boehringer Ingelheim
Castrop-Rauxel
Boehringer Ingelheim
Celle
Boehringer Ingelheim
Chemnitz
Boehringer Ingelheim
Cochem
Boehringer Ingelheim
Coppenbrügge
Boehringer Ingelheim
Crimmitschau
Boehringer Ingelheim
Crivitz
Boehringer Ingelheim
Cuxhaven
Boehringer Ingelheim
Dabel
Boehringer Ingelheim
Darmstadt
Boehringer Ingelheim
Dassow
Boehringer Ingelheim
Datteln
Boehringer Ingelheim
Daun
Boehringer Ingelheim
Deggendorf
Boehringer Ingelheim
Deidesheim
Boehringer Ingelheim
Deining
Boehringer Ingelheim
Delitzsch
Boehringer Ingelheim
Demen
Boehringer Ingelheim
Denkendorf
Boehringer Ingelheim
Dessau
Boehringer Ingelheim
Detmold
Boehringer Ingelheim
Dettenheim
Boehringer Ingelheim
Deuben
Boehringer Ingelheim
Deutzen
Boehringer Ingelheim
Diepholz
Boehringer Ingelheim
Dillingen
Boehringer Ingelheim
Dingolfing
Boehringer Ingelheim
Dinkelsbühl
Boehringer Ingelheim
Dinslaken
Boehringer Ingelheim
Dissen
Boehringer Ingelheim
Dogern
Boehringer Ingelheim
Dollern
Boehringer Ingelheim
Donaueschingen
Boehringer Ingelheim
Dörentrup
Boehringer Ingelheim
Dormagen
Boehringer Ingelheim
Dornstetten
Boehringer Ingelheim
Dörpen
Boehringer Ingelheim
Dorsten
Boehringer Ingelheim
Dortmund
Boehringer Ingelheim
Dreieich
Boehringer Ingelheim
Drensteinfurt
Boehringer Ingelheim
Dresden
Boehringer Ingelheim
Driedorf
Boehringer Ingelheim
Duderstadt
Boehringer Ingelheim
Duisburg
Boehringer Ingelheim
Dummerstorf
Boehringer Ingelheim
Düren
Boehringer Ingelheim
Düsseldorf
Boehringer Ingelheim
Ebergötzen
Boehringer Ingelheim
Ebermannstadt
Boehringer Ingelheim
Eberstadt
Boehringer Ingelheim
Ebhausen
Boehringer Ingelheim
Edewecht
Boehringer Ingelheim
Edling
Boehringer Ingelheim
Egelsbach
Boehringer Ingelheim
Ehingen
Boehringer Ingelheim
Eilenburg
Boehringer Ingelheim
Eisenhüttenstadt
Boehringer Ingelheim
Eiterfeld
Boehringer Ingelheim
Eitorf
Boehringer Ingelheim
Ellwangen
Boehringer Ingelheim
Elmshorn
Boehringer Ingelheim
Emersacker
Boehringer Ingelheim
Emmendingen
Boehringer Ingelheim
Emsdetten
Boehringer Ingelheim
Enger
Boehringer Ingelheim
Enkenbach-Alsenborn
Boehringer Ingelheim
Ennepetal
Boehringer Ingelheim
Ennigerloh
Boehringer Ingelheim
Eppstein
Boehringer Ingelheim
Erding
Boehringer Ingelheim
Erftstadt
Boehringer Ingelheim
Erkrath
Boehringer Ingelheim
Erligheim
Boehringer Ingelheim
Erndtebrück
Boehringer Ingelheim
Erolzheim
Boehringer Ingelheim
Eschborn
Boehringer Ingelheim
Eschelbronn
Boehringer Ingelheim
Eschweiler
Boehringer Ingelheim
Eslohe
Boehringer Ingelheim
Espenhain
Boehringer Ingelheim
Essen
Boehringer Ingelheim
Esslingen am Neckar
Boehringer Ingelheim
Euskirchen
Boehringer Ingelheim
Filderstadt
Boehringer Ingelheim
Floh-Seligenthal
Boehringer Ingelheim
Flöha
Boehringer Ingelheim
Forbach
Boehringer Ingelheim
Forchheim
Boehringer Ingelheim
Frankenberg
Boehringer Ingelheim
Frankenthal
Boehringer Ingelheim
Frankfurt
Boehringer Ingelheim
Freiberg
Boehringer Ingelheim
Freiburg im Breisgau
Boehringer Ingelheim
Freigericht
Boehringer Ingelheim
Freudenstadt
Boehringer Ingelheim
Freyung
Boehringer Ingelheim
Friedland
Boehringer Ingelheim
Friedrichshafen
Boehringer Ingelheim
Friedrichsthal
Boehringer Ingelheim
Frohburg
Boehringer Ingelheim
Fulda
Boehringer Ingelheim
Fürstenwalde
Boehringer Ingelheim
Furtwangen im Schwarzwald
Boehringer Ingelheim
Füssen
Boehringer Ingelheim
Gangelt
Boehringer Ingelheim
Gardelegen
Boehringer Ingelheim
Garmisch-Partenkirchen
Boehringer Ingelheim
Gars
Boehringer Ingelheim
Gebesee
Boehringer Ingelheim
Geesthacht
Boehringer Ingelheim
Gelbensande
Boehringer Ingelheim
Gelsenkirchen
Boehringer Ingelheim
Gensingen
Boehringer Ingelheim
Georgsmarienhütte
Boehringer Ingelheim
Gera
Boehringer Ingelheim
Gerbstedt
Boehringer Ingelheim
Germering
Boehringer Ingelheim
Germersheim
Boehringer Ingelheim
Gevelsberg
Boehringer Ingelheim
Giessen
Boehringer Ingelheim
Gifhorn
Boehringer Ingelheim
Gilserberg
Boehringer Ingelheim
Gladbeck
Boehringer Ingelheim
Gleichen
Boehringer Ingelheim
Goch
Boehringer Ingelheim
Gochsheim
Boehringer Ingelheim
Göllheim
Boehringer Ingelheim
Göllingen
Boehringer Ingelheim
Gomaringen
Boehringer Ingelheim
Göttingen
Boehringer Ingelheim
Grafenau
Boehringer Ingelheim
Gransee
Boehringer Ingelheim
Grassau
Boehringer Ingelheim
Greiz
Boehringer Ingelheim
Greven
Boehringer Ingelheim
Grevesmühlen
Boehringer Ingelheim
Griesheim
Boehringer Ingelheim
Grömitz
Boehringer Ingelheim
Gronau
Boehringer Ingelheim
Groß Grönau
Boehringer Ingelheim
Groß Quenstedt
Boehringer Ingelheim
Groß-Zimmern
Boehringer Ingelheim
Großalmerode
Boehringer Ingelheim
Großbottwar
Boehringer Ingelheim
Großefehn
Boehringer Ingelheim
Großhabersdorf
Boehringer Ingelheim
Großkorbetha
Boehringer Ingelheim
Großlangheim
Boehringer Ingelheim
Grünbach
Boehringer Ingelheim
Gummersbach
Boehringer Ingelheim
Güstrow
Boehringer Ingelheim
Haag
Boehringer Ingelheim
Hagen
Boehringer Ingelheim
Haigerloch
Boehringer Ingelheim
Haldensleben I
Boehringer Ingelheim
Halle
Boehringer Ingelheim
Hamburg
Boehringer Ingelheim
Hamm
Boehringer Ingelheim
Hamminkeln
Boehringer Ingelheim
Hanau
Boehringer Ingelheim
Hanerau-Hademarschen
Boehringer Ingelheim
Hanover
About this study
Official title: Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
- To compare the effect of pramipexole on depressive symptoms in early and advanced PD patients
- To evaluate the course of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADS-D under pramipexole treatment
- To investigate whether improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part III)
Read the detailed description
Study Design:
- Conditions
- Parkinson Disease
- Medical subject headings
- Parkinson Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of depressive symptoms (UPDRS item 3, HADS-D) compared to baseline in early and advanced Parkinsons's disease
Measured: 9-16 weeks
Change in sum scores of UPDRS Part III (motor examination) from baseline and UPDRS Part I (mentation, behavior and mood) from baseline
Measured: 9-16 weeks
Change in HADS subscores (anxiety and depression) from baseline
Measured: 9-16 weeks
Secondary outcomes (3)
Baseline pattern of patient rated symptom list (HADS)
Measured: 9-16 weeks
Correlation of the change in UPDRS Part I and UPDRS Part III at the final visit
Measured: 9-16 weeks
Frequency of adverse events
Measured: 9-16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2007 (estimated)
- Study startMar 2007
- Primary completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 1,192 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Boehringer Ingelheim, Study chair, Boehringer Ingelheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00539214
- Sponsor's protocol ID
- 248.639
- Status last verified
- Oct 2013
- First submitted
- 28 Sep 2007
- Last updated
- 1 Nov 2013
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
- ClinicalTrials.gov ID
- NCT00539214
- Acronym / sponsor ID
- 248.639
- Conditions
- Parkinson Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,192 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Mar 2007
- Primary completion
- Dec 2007 (actual)
- First posted
- 4 Oct 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To compare the effect of pramipexole on depressive symptoms in early and advanced PD patients
- To evaluate the course of depressive symptoms measured with UPDRS Part I (mentation, behavior and mood) and with HADS-D under pramipexole treatment
- To investigate whether improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part III)
Detailed description
Study Design:
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- PD patients
Key inclusion criteria (5 listed)
- Idiopathic Parkinsons disease with or without fluctuations
- Indication for treatment with Sifrol®
- Male or female patients of age
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (HADS)
Key exclusion criteria (2 listed)
- Any contraindications according to the Summary of Product Characteristics (SPC): hypersensitivity to pramipexole or to any of the excipients.
- Ongoing treatment with Sifrol®.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Improvement of depressive symptoms (UPDRS item 3, HADS-D) compared to baseline in early and advanced Parkinsons's disease
Time frame: 9-16 weeks
Change in sum scores of UPDRS Part III (motor examination) from baseline and UPDRS Part I (mentation, behavior and mood) from baseline
Time frame: 9-16 weeks
Change in HADS subscores (anxiety and depression) from baseline
Time frame: 9-16 weeks
3 secondary outcomes
Baseline pattern of patient rated symptom list (HADS)
Time frame: 9-16 weeks
Correlation of the change in UPDRS Part I and UPDRS Part III at the final visit
Time frame: 9-16 weeks
Frequency of adverse events
Time frame: 9-16 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2013.
- Related InfoLink provided by the sponsor.
Related trials for Parkinson Disease
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
Recruiting
Effects of Microelectrode-based Brain Stimulation in Humans
Essential Tremor, Parkinsons Disease (PD)
Not yet recruitingPhase 1
Stanford University Neurofiber Study
PARKINSON DISEASE (Disorder)
Recruiting
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
Healthy Individuals (Controls), Parkinson Disease
Not yet recruiting
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
Idiopathic Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boehringer Ingelheim study chair
Boehringer Ingelheim
317 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Boehringer Ingelheim at 317 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 317 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of depressive symptoms (UPDRS item 3, HADS-D) compared to baseline in early and advanced Parkinsons's disease (time frame: 9-16 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2013.